Articles

GLP-1 Coverage in 2027 Brings New Prices, New Options and Tougher Decisions

3 min read
Clinical Pharmacy ExpertiseWeight Loss Drugs / GLP1s

Share this insight

By Long Tran, PharmD; Beckie Fenrick, PharmD; and Jason Peterson, RPh 

GLP-1 coverage is becoming an even more complicated decision for employers heading into 2027. New manufacturer-direct programs offer alternatives to PBM coverage, expanding clinical indications are raising new benefit design questions and upcoming list-price reductions could change what plans and members alike pay. 

Together, these developments are changing how plan sponsors weigh medication costs against clinical oversight, utilization management, member access and integration with existing benefits for 2027. 

New GLP-1 Indications, Coverage Implications and Safety Updates 

Recent FDA developments are expanding the clinical uses of GLP-1 medications and creating new considerations for employer health plans. 

The FDA recently approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal heart attack or nonfatal stroke, in adults with type 2 diabetes at high risk for these events. 

Meanwhile, Lilly’s Foundayo (orforglipron), a once-daily oral GLP-1 approved for chronic weight management earlier in 2026, could soon receive an additional indication. Phase 3 trials in adults with type 2 diabetes showed significant improvements in blood sugar and weight, and Lilly submitted an application for a diabetes indication in Q2 2026. An FDA decision is expected before the year-end. 

For employers that exclude weight-loss medications, an additional indication could complicate coverage decisions. If Foundayo is approved for type 2 diabetes, plans may need indication-specific prior authorization or other clinical criteria to distinguish covered diabetes treatment from excluded weight-management use, rather than blocking the medication entirely. 

GLP-1 medications also carry risks, including gastrointestinal side effects, pancreatitis, and gallbladder disease. On November 9, 2026, the FDA announced new GLP-1 labeling requirements addressing an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, potentially permanent vision loss. Although the absolute risk remains low, these risks reinforce the importance of appropriate patient selection and ongoing clinical monitoring. 

Comparing Traditional PBM and Manufacturer-Direct GLP-1 Programs 

New GLP-1 access models give employers alternatives to traditional PBM coverage, with different implications for medication costs, utilization management, and member support. 

Within the traditional pharmacy benefit, PBMs manage GLP-1 coverage through formularies, prior authorization, step therapy, and preferred-product strategies. Plans benefit from integrated claims data, while PBM-integrated lifestyle and outcomes programs or vendor partnerships can provide additional support. 

Outside the PBM, two types of arrangements are emerging: 

  • Direct-to-consumer (DTC) programs, including LillyDirect and NovoCare Pharmacy, allow patients to obtain medications through manufacturer-supported channels, including self-pay options. 
  • Direct-to-employer (DTE) arrangements allow employers to contract with programs that combine medication access with benefit administration, clinical oversight, care management and lifestyle support. Services and pricing vary by administrator, and some arrangements may charge program fees separately from medication costs. 

While manufacturer-direct arrangements may offer lower medication prices, they also introduce tradeoffs. When medications are obtained outside the PBM benefit, plans may have less visibility into utilization and fewer opportunities to apply existing formulary controls and prior authorization requirements. Clinical oversight and population health management may also differ. 

Plan sponsors should compare total medication and program costs, clinical oversight, utilization visibility, governance and how each arrangement fits with existing benefits and contracts. 

Novo Nordisk’s 2027 GLP-1 Price Cuts and Their Impact on Plan Costs 

Another major shift is coming to the GLP-1 market in January 2027 with Novo Nordisk announcing plans to reduce the wholesale acquisition cost (WAC), or published list price, of three of its GLP-1 medications: Wegovy, Ozempic and Rybelsus. Starting January 1, all three will carry a monthly list price of $675, representing reductions of approximately 50% for Wegovy and 35% for Ozempic. 

For employers and plan sponsors, lower list prices could change the financial equation. Members may see reduced out-of-pocket costs, particularly when their benefits include deductibles or coinsurance. However, lower WAC prices may also mean smaller manufacturer rebates, potentially changing what plans ultimately pay after rebates and discounts. 

As these changes take effect, employers should reassess their GLP-1 formulary strategies and compare total net costs across traditional PBM coverage and alternative access models. The goal is to understand how the new pricing affects both plan spending and member affordability, while supporting broader obesity-management objectives. 

What Employers Should Reevaluate in Their 2027 GLP-1 Strategy 

A lower drug price may look compelling, but plan sponsors still need to understand how a GLP-1 program will function in practice. If a plan excludes weight-loss medications, how will it distinguish covered diabetes treatment from excluded uses? Who will oversee clinical care and monitor outcomes? Will the employer have the data needed to track utilization and measure the program’s full cost? These are the questions that should guide GLP-1 coverage decisions heading into 2027. 

By evaluating available options against their employee population’s needs, clinical oversight, member experience, integration with existing benefits and total financial impact, employers can choose an approach that balances affordability and access while supporting appropriate medication use and long-term health outcomes. 

Featured Insights

Explore the latest market trend and insights from our Rx experts.